Skip to main content

Table 1 Patient characteristics (n = 23)

From: Assessing regional hepatic function changes after hypertrophy induction by radioembolisation: comparison of gadoxetic acid-enhanced MRI and 99mTc-mebrofenin hepatobiliary scintigraphy

Clinical data

 Age (min–max) (years)

66

(59–74)

 Male/female

17/6

(73.9%/26.1%)

 Liver cirrhosis

0

0%

 Liver steatosis

5

21.7%

 Previous chemotherapy

17

73.9%

 Previous liver resection

4

17.4%

Primary tumour

 Colorectal cancer

11

47.8%

 Cholangiocellular carcinoma

4

13.0%

 Breast cancer

3

17.3%

 Hepatocellular carcinoma

1

4.3%

 Neuroendocrine tumour

1

4.3%

 Renal cell carcinoma

1

4.3%

 Oesophageal carcinoma

1

4.3%

 Pancreatic ductal adenocarcinoma

1

4.3%

 Mean (SD) 90Y dose to RLL (Gy/mL)

45.7

(7.5)

  1. Data are absolute number and percentages unless differently indicated
  2. RLL Right liver lobe, SD Standard deviation